shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required)

    RFA-DA-25-057

    National Institutes of Health

    Opening date 27 Jun 2024, 12:00AM

    Closing date 27 Nov 2024, 12:00AM

    Funding Opportunity Number: RFA-DA-25-057

    Opportunity Category: Discretionary

    CFDA Number(s): 93.279 -- Drug Abuse and Addiction Research Programs

    Cost Sharing or Matching Requirement: No

    Posted Date: Jun 27, 2024 12:00:00 AM EDT

    Closing Date: Nov 27, 2024 12:00:00 AM EST

    Award Ceiling: $500000

    Award Floor: none

    Eligible Applicants: County governments,Small businesses,Public housing authorities/Indian housing authorities,Others (see text field entitled "Additional Information on Eligibility" for clarification),Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,For profit organizations other than small businesses,Private institutions of higher education,Independent school districts,State governments,Special district governments,Native American tribal governments (Federally recognized),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,City or township governments,Public and State controlled institutions of higher education,Native American tribal organizations (other than Federally recognized tribal governments)

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Agency Name: National Institutes of Health

    Description: Stimulant Use Disorder still does not have FDA- approved treatments. Neuromodulation, such as, for example, transcranial magnetic stimulation (TMC) has been successfully used for more than 10 years in major depressive disorder (MDD) where patients have failed one antidepressant and since 2018 it has been used for obsessive-compulsive disorder (OCD). Another example is transcranial direct current stimulation (tDCS) which is currently being developed for a range of mental and neurological conditions, and some of them have direct relevance for StUD vulnerable phenotype (cognitive dysfunction, compulsive, and impulsive traits). Other neuromodulation technologies potentially can also be applied to StUD. As not everyone who takes drugs becomes addicted, and while the StUD population's extreme heterogeneity represents a barrier to effective treatment development, there is a treatment gap that needs to be filled, especially for the high-risk vulnerable phenotype with low executive function and difficulties with response regulation - anxious-impulsive traits. Developing neuromodulation combined with behavioral treatment modalities (CBT, mindfulness-based approaches) that will help to maintain use decrease and prevent relapse would have tremendous value as a treatment option. Randomized controlled trials are needed to develop the treatment algorithms and to select the most efficacious one.

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept